US Stock Market Move | Burning Rock Biotech Ltd. Sponsored ADR Class A (BNR.US) rose more than 10% as it developed the OncoCompass technology to empower precise diagnosis and treatment of tumors.

Following a sharp increase of 18.49% in stock price yesterday, on Thursday, Burning Rock Biotech Ltd. Sponsored ADR Class A (BNR.US) surged over 10% again, reaching $31.483. In terms of news, recently, Burning Rock Biotech Ltd. Sponsored ADR Class A presented two research findings at the San Antonio Breast Cancer Symposium (SABCS) and ASCO Gastrointestinal Cancers Symposium (ASCO-GI), focusing on the clinical application of liquid biopsy technology for breast cancer (BC) and colorectal cancer (CRC), providing new solutions for low-abundance mutation detection and minimal residual disease (MRD) detection, and contributing to the exploration of precise and innovative diagnosis and treatment technologies for cancer. Traditional tissue biopsies are invasive and unable to meet the clinical needs for long-term monitoring of BC, while liquid biopsy, by analyzing ctDNA in blood, provides a minimally invasive alternative for BC diagnosis and treatment. Addressing the clinical challenge of difficulty in ctDNA detection under low tumor burden, Burning Rock Biotech Ltd. Sponsored ADR Class A has developed the OncoCompass ultra-deep targeted sequencing technology, combining machine learning, aiming to improve the accuracy and reliability of low-abundance ctDNA detection. By combining ultra-deep sequencing technology with machine learning innovation, Burning Rock OncoCompass has overcome the technical bottleneck of low-abundance ctDNA detection, effectively addressing the core challenges of monitoring BC treatment efficacy and predicting relapse, providing a practical mutation detection tool for BC patients with low tumor levels, further expanding the application boundaries of liquid biopsy in the field of precision cancer diagnosis and treatment.